
Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

ViaNautis Bio Ltd closes US$25m Series A financing
The US$25m round of cambridge-based ViaNautis Bio Ltd, founded in 2018 as SomaServe, was led 4BIO Capital, BGF (both UK), and UCB Ventures (UK, US,...

Evotech screens cancer candidates for Dewpoint Therapeutics
With this partnership, the Hamburg-based screening specialists have landed a really big deal Dewpint Therapeutics, the just four-year-old spin-off...

Pierre Fabre Laboratories collaborate with Vernalis
The French biotech company combines its experience in innovation, development, manufacturing, and commercialisation in oncology with the expertise of...

Joining forces for mRNA breakthrough
Global biotech Dyadic International Inc. and French bYoRNA SAS officially sealed a strategic partnership on the 26th of September aimed at advancing...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...